All Videos

Rethink seborrheic dermatitis care: limit facial steroids, use antifungals wisely, and watch emerging barrier-safe targeted therapies.

Early seborrheic dermatitis treatment reduces inflammation, prevents worsening, and boosts quality of life; experts explain pediatric vs adult goals and mask-triggered flares.

Experts discuss strategies for managing patient remission in psoriatic arthritis, emphasizing personalized treatment plans and ongoing patient engagement.

Explore the impact of patient-centered approaches in dermatology, emphasizing long-term success and quality of life in psoriasis treatment.

Dr. Madigan explains that for a patient with newly diagnosed indolent systemic mastocytosis (ISM), initial management focuses on best supportive therapies like cetirizine and cromolyn sodium while emphasizing that an epinephrine auto-injector is a mandatory component of care due to high anaphylaxis risks.

Ruiz Dasilva emphasized case-based strategies for managing complex inflammatory dermatoses, highlighted chronic pruritus as an urgent unmet need, and called for more standardized designs for atopic dermatitis trials.

James Del Rosso, DO, shares rapid-fire insights on mentorship, HS advances, contact dermatitis triggers, and teen skin care marketing concerns.

This episode, titled Seborrheic Dermatitis Across Skin Tones and Long-Term Disease Burden, features dermatology experts discussing the following critical questions: How might presentation of SD differ in various skin tones? What challenges do you encounter when diagnosing SD in patients with skin color? In your experience, what long-term complications arise when SD is inadequately treated or remains uncontrolled over time?

Seborrheic dermatitis varies by age, affects scalp and face, drives itching and stigma, and lowers quality of life—highlighting newer targeted treatments.

Recent data reveals insights on psoriasis treatment, highlighting the importance of achieving full clearance for long-term control and patient outcomes.

Healthcare professionals discuss evaluating disease control and treatment response using objective findings and patient assessments in dermatology.

At Winter Clinical Miami, Lisa Swanson, MD, FAAD, shared practical, prior authorization–free treatment strategies while calling for expanded therapeutic options and earlier research inclusion for children under 12.

Nicholas Brownstone, MD, showcased multidisciplinary collaboration and educational podcast initiatives aimed at supporting both dermatology trainees and patients.

Harrison Nguyen, MD, MBA, MPH, FAAD, shares early career billing, coding, and mentorship tips for dermatologists at Winter Clinical Miami 2026.

At Winter Clinical Miami 2026, Linda Stein Gold, MD, FAAD, shared acne and rosacea tips and previewed psoriasis oral advances like icotrokinra.

Mark Lebwohl, MD, shares his Winter Clinical Miami 2026 highlights, including oral psoriasis peptides, atopic dermatitis advances, GLP-1 combos, and more.

Systemic mastocytosis often hides behind common symptoms; learn why early, team-based diagnosis and tailored staging prevent delays and risks.

In a Derm Dispatch discussion, Renata Block, DMSc, MMS, PA-C, and Lauren Madigan, MD, review practical strategies for diagnosing and managing cutaneous mastocytosis across age groups.

Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, and Shanna Miranti, MPAS, PA-C, discuss how “taking off the clinician mask” can strengthen trust and improve shared decision-making in the exam room.

In this first episode, Dr. Hadar Lev-Tov and Dr. Martina Porter convene for a clinical journal club to discuss the emerging landscape of Hidradenitis Suppurativa (HS) treatment.

Joni Jefferson, DO, spotlights skin of color dermatology, safer lasers, mentorship, and the future of aesthetic medicine during Black History Month.

In an interview with Dermatology Times, Michael O’Donoghue, MD, describes how a standardized protocol supports efficient and consistent delivery of photodynamic therapy.

BE HEARD long-term data show bimekizumab (Bimzelx) IL‑17A/F reduces hidradenitis suppurativa draining tunnels while boosting IHS4 and quality of life.

Experts discuss how seborrheic dermatitis can be distinguished from atopic dermatitis and psoriasis through clinical features and underlying immune patterns, highlighting the role of Th17/Th22-driven inflammation and barrier dysfunction in guiding more precise, targeted treatment strategies.

Experts discuss how seborrheic dermatitis arises from a multifactorial interplay of immune dysregulation, Malassezia yeast colonization, epidermal barrier impairment, and sebaceous gland activity, shaping its chronic nature and informing targeted treatment approaches.

Experts discuss the complexities of treating psoriatic arthritis, emphasizing the need for a multifaceted approach and potential medication switches.

Explore the complexities of managing psoriatic arthritis in dermatology, focusing on effective treatment strategies and patient care insights.

Patient advocate Suki Tipp details her progression from misattributed cutaneous findings and fragmented specialty care to life-threatening anaphylaxis and eventual disease control with targeted therapy.

Thrasyvoulos Tzellos, MD, PhD, explains HS’s progressive toll and how UCB’s BE HEARD bimekizumab data shows durable tunnel reduction and lasting disease improvement.

In a conversation with Dermatology Times, Del Rosso highlighted the growing range of systemic and procedural therapies available to clinicians.